143 related articles for article (PubMed ID: 10093040)
1. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors.
Khleif SN; Abrams SI; Hamilton JM; Bergmann-Leitner E; Chen A; Bastian A; Bernstein S; Chung Y; Allegra CJ; Schlom J
J Immunother; 1999 Mar; 22(2):155-65. PubMed ID: 10093040
[TBL] [Abstract][Full Text] [Related]
2. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Abrams SI; Khleif SN; Bergmann-Leitner ES; Kantor JA; Chung Y; Hamilton JM; Schlom J
Cell Immunol; 1997 Dec; 182(2):137-51. PubMed ID: 9514698
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
4. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
5. Mutated Ras peptides as vaccines in immunotherapy of cancer.
Gjertsen MK; Gaudernack G
Vox Sang; 1998; 74 Suppl 2():489-95. PubMed ID: 9704487
[TBL] [Abstract][Full Text] [Related]
6. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Gjertsen MK; Bjorheim J; Saeterdal I; Myklebust J; Gaudernack G
Int J Cancer; 1997 Sep; 72(5):784-90. PubMed ID: 9311595
[TBL] [Abstract][Full Text] [Related]
8. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
9. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors.
Rahma OE; Hamilton JM; Wojtowicz M; Dakheel O; Bernstein S; Liewehr DJ; Steinberg SM; Khleif SN
J Transl Med; 2014 Feb; 12():55. PubMed ID: 24565030
[TBL] [Abstract][Full Text] [Related]
10. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
[TBL] [Abstract][Full Text] [Related]
11. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
[TBL] [Abstract][Full Text] [Related]
12. Mutant ras epitopes as targets for cancer vaccines.
Abrams SI; Hand PH; Tsang KY; Schlom J
Semin Oncol; 1996 Feb; 23(1):118-34. PubMed ID: 8607022
[TBL] [Abstract][Full Text] [Related]
13. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Meyer RG; Korn S; Micke P; Becker K; Huber C; Wölfel T; Buhl R
Lung Cancer; 2007 Oct; 58(1):88-94. PubMed ID: 17599645
[TBL] [Abstract][Full Text] [Related]
14. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
15. p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Fossum B; Gedde-Dahl T; Breivik J; Eriksen JA; Spurkland A; Thorsby E; Gaudernack G
Int J Cancer; 1994 Jan; 56(1):40-5. PubMed ID: 7903287
[TBL] [Abstract][Full Text] [Related]
16. Mutated Ras-transfected, EBV-transformed lymphoblastoid cell lines as a model tumor vaccine for boosting T-cell responses against pancreatic cancer: a pilot trial.
Kubuschok B; Pfreundschuh M; Breit R; Hartmann F; Sester M; Gärtner B; König J; Murawski N; Held G; Zwick C; Neumann F
Hum Gene Ther; 2012 Dec; 23(12):1224-36. PubMed ID: 22966960
[TBL] [Abstract][Full Text] [Related]
17. Comparison of linear and branched peptide forms (MAPs) in the induction of T helper responses to point-mutated ras immunogens.
Schott ME; Wells DT; Schlom J; Abrams SI
Cell Immunol; 1996 Dec; 174(2):199-209. PubMed ID: 8954620
[TBL] [Abstract][Full Text] [Related]
18. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.
Luo Y; Chen X; Han R; Chorev M; Dewolf WC; O'Donnell MA
J Urol; 1999 Oct; 162(4):1519-26. PubMed ID: 10492248
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
[TBL] [Abstract][Full Text] [Related]
20. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.
Abou-Alfa GK; Chapman PB; Feilchenfeldt J; Brennan MF; Capanu M; Gansukh B; Jacobs G; Levin A; Neville D; Kelsen DP; O'Reilly EM
Am J Clin Oncol; 2011 Jun; 34(3):321-5. PubMed ID: 20686403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]